

NEW Biosimilar Antibodies

PD-1 | Nivolumab Biosimilar
PD-L1 | Atezolizumab Biosimilar
CTLA-4 | Ipilimumab Biosimilar
and more

DISCOVER

BioCell



Correction: Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma

This information is current as of January 27, 2022.

Anusha-Preethi Ganesan, Magnus Johansson, Brian Ruffell, Adam Yagui-Beltrán, Jonathan Lau, David M. Jablons and Lisa M. Coussens

J Immunol 2013; 191:5319; ;

doi: 10.4049/jimmunol.1390059

<http://www.jimmunol.org/content/191/10/5319>

Why *The JI*? [Submit online.](#)

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at: <http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at: <http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: <http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



Corrections

Ganesan, A.-P., M. Johansson, B. Ruffell, A. Beltran, J. Lau, D. M. Jablons, and L. M. Coussens. 2013. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. *J Immunol.* 191: 2009–2017.

The fourth author's name was published incorrectly. The correct name is Adam Yagui-Beltrán.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1390059